GLP-1 Side Effects: What Is Normal, What Is Not, and How to Manage Them

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Individual results may vary. Compounded semaglutide and tirzepatide are not FDA-approved finished products and are not the same as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Please consult a licensed physician before starting, adjusting, or stopping any GLP-1 medication to determine whether it is appropriate for your specific health history and concerns.

What to Expect When You Start a GLP-1 Medication

GLP-1 receptor agonists — including semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) — are among the most clinically studied weight management and diabetes medications available. They work by mimicking the naturally occurring glucagon-like peptide-1 hormone, which slows gastric emptying, signals satiety to the brain, and helps regulate insulin secretion. That mechanism is responsible for their effectiveness — and for the majority of their side effects.

Most side effects are gastrointestinal in nature, dose-dependent, and temporary. They tend to be most noticeable in the first one to four weeks of treatment and at each dose increase, then gradually diminish as the body adjusts. Understanding what is normal, what can be managed at home, and what requires a call to your provider is the most important knowledge you can have when starting GLP-1 therapy.

This page covers:

• The most common GLP-1 side effects, how they work mechanically, and how to manage them
• The side effects that are less common but worth knowing about
• The serious warning signs that require prompt medical attention
• Who should not take GLP-1 medications
• A week-by-week overview of what the adjustment period typically looks like

How GLP-1 Medications Cause Side Effects: The Mechanism

Before reviewing individual side effects, it is useful to understand why they occur.

GLP-1 receptor agonists activate receptors throughout the gastrointestinal tract and in brainstem regions that regulate nausea and appetite. The primary mechanism responsible for most side effects is delayed gastric emptying: food moves from the stomach into the small intestine more slowly than it normally would. When food lingers in the stomach, symptoms such as nausea, bloating, fullness, and in some cases vomiting can follow.

GLP-1 receptors are also present in the area postrema — a region of the brainstem involved in the vomiting reflex — which means the medication can directly stimulate nausea pathways independent of what you eat (Bhatt et al., Journal of Clinical Medicine, 2023).

The practical implication: eating large meals, high-fat meals, or eating too quickly will significantly worsen side effects, because they compound the gastric slowing the medication is already producing.

Common GLP-1 Side Effects and How to Manage Them

Nausea

Nausea is the most frequently reported adverse effect across all GLP-1 clinical programs. According to FDA prescribing information and clinical trial data, nausea occurs in approximately 15–30% of patients at standard doses, rising to 30–44% at higher maintenance doses of semaglutide and tirzepatide (Novo Nordisk, Prescribing Information for Wegovy; Eli Lilly, Prescribing Information for Zepbound). A 2024 systematic review of semaglutide RCTs reported mean nausea incidence ranging from approximately 2% to 20% across different dosing stages, with symptoms predominantly mild to moderate and transient (Feier et al., International Journal of Molecular Sciences, 2024).

Why it happens: Delayed gastric emptying causes food to sit in the stomach longer, and GLP-1 receptor activation in the brainstem directly stimulates nausea pathways.

When it typically occurs: Nausea is most pronounced in the first one to three days after each dose increase. It generally improves within one to two weeks as the body adjusts.

How to manage it:

• Eat smaller portions — aim for meals that are roughly 30–50% of your usual volume
• Eat slowly and stop at the point of comfortable satiation, not fullness
• Avoid high-fat, fried, or heavily spiced foods, which slow gastric emptying further
• Avoid lying down within two to three hours of eating
• Take your injection at a consistent time; some patients find evening dosing reduces waking-hours nausea
• If nausea is significant, bland, low-fat foods (crackers, toast, plain rice, broths) are easier to tolerate
• Do not skip meals entirely — eating nothing can sometimes worsen nausea on these medications

When to call your provider: Nausea that does not improve within two weeks at a given dose, or nausea that is severe enough to prevent adequate fluid intake, warrants a dose conversation. Your provider may pause your titration at the current dose for an additional four weeks before increasing, which clinical evidence supports as an effective strategy for reducing gastrointestinal burden (Eldor et al., Diabetes Care, 2025).

Vomiting

Vomiting is less common than nausea but is reported by approximately 6–10% of patients during titration, according to clinical trial data for semaglutide (Feier et al., International Journal of Molecular Sciences, 2024). It typically follows the same pattern as nausea — peaking after each dose increase and improving within one to two weeks.

How to manage it:

• Small, frequent sips of water or electrolyte beverages rather than drinking large amounts at once
• Avoid solid food during active vomiting episodes; reintroduce gradually once symptoms ease
• Rest in an upright or semi-reclined position
• Contact your provider if vomiting persists beyond 24–48 hours without improvement

When to call your provider immediately: Vomiting severe enough to prevent keeping any fluids down, or vomiting lasting more than 24–48 hours, carries a risk of dehydration that requires medical evaluation. Dehydration in the context of GLP-1 use can also affect kidney function in some patients. Do not attempt to manage persistent vomiting with home remedies alone — contact your prescribing provider.

Diarrhea

Diarrhea affects approximately 10–30% of patients, depending on the medication and dose, and tends to be mild to moderate in severity (Novo Nordisk, Prescribing Information for Wegovy). Like nausea, it is most common during early treatment and at dose escalations.

Why it happens: GLP-1 receptors are present throughout the gastrointestinal tract. Activation of these receptors affects intestinal motility, which can accelerate transit time and produce loose or more frequent stools.

How to manage it:

• Stay well hydrated — replace fluids and electrolytes lost through frequent stools
• Reduce high-fiber foods temporarily if symptoms are significant, then reintroduce gradually
• Avoid sugar alcohols (sorbitol, xylitol) found in many sugar-free products, as these independently worsen diarrhea
• Limit caffeine and alcohol during flares, as both can increase gut motility
• Over-the-counter options such as loperamide may help short-term; ask your provider before using

When to call your provider: Diarrhea lasting more than two weeks at a given dose, diarrhea containing blood, or diarrhea severe enough to cause significant dehydration requires evaluation.

Constipation

Constipation affects approximately 5–12% of patients on GLP-1 medications (Eli Lilly, Prescribing Information for Zepbound) and is more common in the first few weeks of treatment. It may seem paradoxical given that diarrhea is also reported — the reality is that different patients respond differently to the medication's effects on gut motility.

Why it happens: While delayed gastric emptying primarily affects the stomach, the net effect on the entire GI tract can slow motility throughout, particularly in the colon. Reduced food intake on these medications — which means less fiber and less bulk — also contributes.

How to manage it:

• Increase dietary fiber intake gradually (target 25–35g per day from vegetables, legumes, whole grains)
• Drink at least 8–10 glasses of water daily
• Incorporate regular physical movement, even short walks, which supports bowel motility
• Stool softeners such as polyethylene glycol (MiraLAX) or docusate sodium are generally safe to use; confirm with your provider
• Do not strain — prolonged straining can cause complications unrelated to the medication itself

Acid Reflux and Heartburn (GERD)

Because GLP-1 medications slow gastric emptying, they can worsen acid reflux in patients who are already prone to it, or trigger new reflux symptoms. Patients with a known history of gastroesophageal reflux disease (GERD) should discuss this risk with their provider before starting.

How to manage it:

• Avoid lying down within three hours of eating
• Elevate the head of your bed by 6–8 inches if nighttime symptoms occur
• Reduce trigger foods: caffeine, carbonated beverages, alcohol, tomato-based foods, citrus, chocolate, and peppermint
• Antacids may help with mild symptoms; discuss proton pump inhibitors (PPIs) with your provider if symptoms are persistent

Fatigue and Low Energy

Mild fatigue is reported by some patients, particularly in the first two to four weeks of treatment. In most cases, this is not a direct effect of the medication on energy systems but rather reflects the significant reduction in calorie intake that GLP-1 medications produce.

Why it happens: The body requires an adaptation period when caloric intake drops substantially. Reduced intake of carbohydrates, in particular, can cause some patients to experience tiredness or brain fog, especially if they are not consuming adequate protein and fluids.

How to manage it:

• Prioritize protein at every meal — a minimum of 25–30g per meal is recommended to preserve lean mass and support energy levels
• Avoid skipping meals; aim for consistent, balanced, smaller meals throughout the day
• Maintain hydration, as even mild dehydration contributes to fatigue
• Reduce excessive exercise in the first few weeks; light to moderate activity is appropriate

Injection Site Reactions

Mild redness, bruising, or discomfort at the injection site are common and generally resolve within one to two days.

How to manage it:

• Rotate injection sites consistently — recommended locations include the abdomen (at least 2 inches from the navel), the outer thigh, and the upper arm
• Let the medication reach room temperature before injecting (remove from the refrigerator 30 minutes prior)
• Clean the injection site with an alcohol swab and allow it to dry before injecting
• Do not inject into areas with bruising, scar tissue, or skin changes
• Apply gentle pressure after the injection; do not rub the site

When to call your provider: Signs of infection — increasing redness, warmth, swelling, or discharge — require evaluation. Significant skin reactions beyond mild redness are not expected and should be reported.

Less Common Side Effects Worth Knowing About

Hair Thinning (Telogen Effluvium)

Hair loss — specifically a pattern called telogen effluvium, where a higher-than-normal percentage of hair follicles enter a resting and shedding phase — has been reported in patients using GLP-1 medications for weight loss. A 2025 scoping review synthesizing data from nine studies, including randomized clinical trials and pharmacovigilance analyses, found more than 1,000 spontaneous reports in the United States and identified telogen effluvium and androgenetic alopecia as the most frequent subtypes reported (PMC, 2025).

Importantly, it is not fully established whether the hair loss is caused directly by the medication or by the rapid calorie deficit and weight loss the medication produces. Significant calorie restriction and rapid weight change are well-documented independent triggers of telogen effluvium regardless of the method of weight loss.

What to know:

• Hair thinning typically becomes noticeable three to six months after significant weight loss begins
• It is almost always temporary — hair regrowth generally occurs within six to twelve months as the body stabilizes
• Adequate protein intake (at least 1.2–1.5g per kilogram of body weight per day) and micronutrient sufficiency (iron, zinc, biotin) may help reduce the severity
• Discuss hair changes with your provider if they are significant or distressing

Increased Heart Rate

GLP-1 receptor agonists can produce a small, modest increase in resting heart rate, typically in the range of 2–4 beats per minute (bpm), based on clinical trial data. This is generally not clinically significant in patients without pre-existing cardiac conditions, but it is worth monitoring.

When to call your provider: A sustained or significant increase in resting heart rate, palpitations, or feelings of pounding heartbeat should be reported, particularly in patients with a history of cardiac arrhythmia.

Headaches

Mild headaches during the initial weeks of treatment are reported by some patients and are generally related to reduced calorie intake, dehydration, or changes in blood sugar regulation. They typically resolve as the body adjusts.

How to manage it: Stay well hydrated, maintain consistent meal timing, and ensure adequate protein intake. Over-the-counter analgesics such as acetaminophen are generally appropriate for mild headaches; consult your provider if headaches are frequent or severe.

Burping or Sulfur Burps

Some patients report frequent burping or, less commonly, burps with an unpleasant sulfur-like odor. This occurs because delayed gastric emptying allows food to ferment longer in the stomach, producing gas and altered digestive byproducts.

How to manage it: Eat more slowly, avoid carbonated beverages, and reduce high-sulfur foods (eggs, cruciferous vegetables, red meat, garlic, and onion) temporarily if the symptom is bothersome. This typically improves as the body adjusts to the medication.

GLP-1 Side Effects: What Is Not Normal — Red Flag Symptoms

While the majority of GLP-1 side effects are mild and manageable, a small subset of symptoms requires immediate medical attention. Do not manage the following at home.

⚠ Pancreatitis (Severe Abdominal Pain)

Pancreatitis — inflammation of the pancreas — is a rare but serious potential complication associated with GLP-1 use. A 2025 meta-analysis analyzing 62 randomized controlled trials with 66,232 patients found a statistically significant association between GLP-1 receptor agonist use and pancreatitis risk (relative risk 1.44, 95% CI 1.09–1.89) (Wen et al., 2025, as cited by The RX Index, 2026). While the absolute risk remains low, pancreatitis is a medical emergency and cannot be managed at home.

Warning signs — seek emergency care immediately:

• Severe, constant abdominal pain that may radiate to the back
• Pain that does not improve with position changes
• Pain accompanied by nausea and vomiting
• Abdominal tenderness when touched
• Fever accompanying abdominal pain

Who is at higher risk: Patients with a history of pancreatitis, active alcohol use disorder, high triglycerides, or gallstones should discuss these risk factors with their provider before starting GLP-1 therapy.

⚠ Gallbladder Disease (Gallstones and Cholecystitis)

Gallstone formation and gallbladder inflammation (cholecystitis) are listed as known risks on GLP-1 medication labels. The risk is related to two factors: a direct effect on gallbladder motility from the medication, and the well-established relationship between rapid weight loss and gallstone formation, regardless of how that weight loss is achieved (PharmaPhorium, January 2026).

Warning signs — seek emergency care immediately:

• Persistent pain in the upper right abdomen or between the shoulder blades
• Fever and chills accompanying abdominal pain
• Jaundice: yellowing of the skin or whites of the eyes
• Clay-colored or pale stools paired with dark urine
• Nausea and vomiting that accompanies upper abdominal pain

⚠ Severe Dehydration from Persistent Vomiting or Diarrhea

While vomiting and diarrhea are common GLP-1 side effects, persistent episodes that prevent adequate fluid intake carry a real risk of dehydration and associated kidney stress. GLP-1 medications are not directly nephrotoxic, but acute kidney injury can occur as a secondary consequence of severe dehydration (GoodRx, updated November 2025).

Signs of significant dehydration requiring medical evaluation:

• Unable to keep any fluids down for more than 24 hours
• Significantly reduced urination or dark-colored urine
• Dizziness or lightheadedness when standing
• Rapid heartbeat
• Confusion or extreme weakness

⚠ Thyroid Warning — Lump or Neck Swelling

GLP-1 receptor agonists carry an FDA boxed warning — the most serious category of warning — regarding the potential for thyroid C-cell tumors, based on findings in rodent studies. In rodent models, prolonged high-dose GLP-1 receptor stimulation produced C-cell hyperplasia and medullary thyroid carcinoma.

The human data, as of 2025–2026, is reassuring but incomplete. A systematic review of 10 RCTs involving 7,830 patients on semaglutide found thyroid cancer incidence below 1%, suggesting no significant elevation in risk in the general population (Feier et al., International Journal of Molecular Sciences, 2024). Large cohort studies in 2024–2025 have not found a substantial increase in thyroid cancer in general users (Baxter et al., Thyroid, 2025; Pasternak et al., BMJ, 2024, as cited by The RX Index, 2026). However, the boxed warning remains, and longer-term data continues to be collected.

The boxed warning is a firm contraindication for patients with:

• A personal history of medullary thyroid carcinoma (MTC)
• A family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Report the following symptoms to your provider promptly:

• A lump or mass in the neck
• Unexplained hoarseness or voice changes
• Difficulty swallowing
• Persistent neck pain

⚠ Allergic Reaction

Serious hypersensitivity reactions, while rare, have been reported. Signs of a severe allergic reaction require immediate emergency care.

Warning signs:

• Hives, rash, or widespread itching
• Swelling of the face, lips, tongue, or throat
• Difficulty breathing or swallowing
• Rapid heartbeat or dizziness
• Loss of consciousness

If you experience any of these symptoms, call 911 or go to the nearest emergency room immediately.

Who Should Not Take GLP-1 Medications

GLP-1 receptor agonists are contraindicated in certain patient populations. This is not a complete list — always disclose your full medical history to your prescribing provider.

Absolute contraindications include:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide, tirzepatide, or any component of the formulation

Conditions requiring careful evaluation and provider discussion:

• History of pancreatitis
• History of gallstones or gallbladder disease
• Gastroparesis (severely delayed gastric emptying) — as of January 2025, the Ozempic label states these medications are "not recommended in patients with severe gastroparesis"
• History of significant gastrointestinal disease, including inflammatory bowel disease
• Pregnancy or active planning of pregnancy — GLP-1 medications should be discontinued at least two months before a planned pregnancy based on current clinical guidance; they are not recommended during pregnancy or breastfeeding
• History of diabetic retinopathy — rapid improvement in blood sugar control associated with GLP-1 therapy has been associated with worsening of diabetic retinopathy in some patients; ophthalmologic screening is recommended before starting in patients with this history (JAMA Ophthalmology, 2024, as cited by The RX Index, 2026)
• Type 1 diabetes mellitus — GLP-1 receptor agonists are not approved for Type 1 diabetes management
• Patients taking other diabetes medications that lower blood sugar (sulfonylureas, insulin) — dose adjustments may be required to avoid hypoglycemia

GLP-1 Side Effects: A Week-by-Week Overview

The following is a general framework based on clinical trial data and real-world prescribing experience. Individual experiences vary, and this should not replace guidance from your own provider.

Weeks 1–2 (Starting dose — typically 0.25 mg semaglutide or 2.5 mg tirzepatide): Most patients experience some nausea during this period, particularly in the first two to three days after the injection. Gastrointestinal symptoms — nausea, mild bloating, loose stools, or some constipation — are at their most unpredictable. Appetite reduction often begins within the first week, which can cause patients to eat less than they realize, leading to mild fatigue.

Weeks 3–4 (Still at starting dose): Side effects typically begin to improve. The body is beginning to adapt to gastric slowing, and most patients find that following the dietary adjustments above significantly reduces nausea. Energy levels stabilize for most patients.

Weeks 5–8 (First dose increase in most protocols): The cycle of mild side effects restarts when the dose increases, mirroring the Week 1–2 experience but generally at reduced severity for most patients. Patients who experienced significant side effects at the starting dose should inform their provider before a dose increase — titration schedules are adjustable.

Month 3 and beyond: For most patients, gastrointestinal side effects have substantially resolved by this stage. Some degree of ongoing nausea at the upper range of the dose titration is normal and expected, but it should not be constant or incapacitating. Hair thinning, if it is going to occur, may become noticeable during this window as weight loss accelerates.

Practical Tips for Reducing Side Effects During GLP-1 Treatment

These are the most clinically supported strategies for minimizing the burden of GLP-1 side effects:

Eat smaller, slower, lower-fat meals. This is the single most effective adjustment most patients can make. High-fat foods are the most common dietary trigger for worsening nausea on these medications.

Stay consistently hydrated. Adequate hydration supports every system in the body and reduces the severity of several GLP-1 side effects, including constipation, headaches, and fatigue.

Prioritize protein. Aim for a minimum of 25–30g of protein per meal. Adequate protein intake helps preserve lean muscle mass during weight loss, supports satiety, and reduces the fatigue associated with calorie restriction.

Do not rush dose titration. Studies published in Diabetes Care (2025) found that a flexible, extended titration schedule — holding the dose for longer before increasing — resulted in better treatment adherence and fewer adverse events compared to standard label-recommended titration schedules (Eldor et al., Diabetes Care, 2025).

Time your injection strategically. Some patients find that administering their weekly injection in the evening on Friday reduces the impact of nausea on workdays. There is no clinically mandated time of day — consistency of day and approximate time matters more than the specific hour.

Avoid alcohol, especially in early weeks. Alcohol irritates the gastrointestinal tract, slows motility, and interacts with the appetite effects of GLP-1 medications in ways that can worsen nausea and impair blood sugar regulation.

Communicate regularly with your provider. Side effects that do not improve within two weeks at a given dose, that are severe, or that interfere with your ability to function should be discussed with your provider. Dose adjustment and titration pace are clinical tools — they are not concessions or failures.

When to Call vs. When to Go to the ER

Frequently Asked Questions

How long do GLP-1 side effects last? Most GLP-1 side effects, particularly gastrointestinal symptoms, peak in the first one to three days after each dose increase and improve substantially within one to two weeks. For many patients, side effects are minimal or absent once a stable dose is reached. Some patients experience ongoing mild nausea at higher doses — this is generally manageable and does not require stopping the medication. Side effects that persist beyond two to four weeks at an unchanged dose warrant a conversation with your provider.

Are GLP-1 side effects the same for semaglutide and tirzepatide? Both medications share similar gastrointestinal side effect profiles because both delay gastric emptying. Clinical data suggests semaglutide produces nausea in approximately 20–30% of patients at standard doses, while tirzepatide — which activates both GLP-1 and GIP receptors — produces nausea in approximately 25–35% of patients at higher doses (PlexusDx, June 2026, citing FDA prescribing information). Individual responses vary considerably, and some patients do better on one medication than the other. Your prescribing provider can help determine which option is appropriate for your situation.

Can GLP-1 side effects be dangerous? The majority of GLP-1 side effects are mild and self-limiting. However, a minority of patients experience serious adverse events — including pancreatitis, gallbladder disease, or severe dehydration — that require medical attention. Knowing the warning signs (severe abdominal pain, inability to keep fluids down, jaundice, or a neck lump) and responding to them promptly is essential. Do not attempt to manage these symptoms at home.

What should I eat to avoid nausea on GLP-1 medications? The most effective dietary approach is to eat smaller portions of low-fat, easily digestible foods and to stop eating before you feel full. Bland foods — plain crackers, toast, boiled or baked chicken, white rice, broths, and cooked vegetables — are typically the best tolerated. Avoid fried foods, heavily spiced meals, high-fat dairy, and alcohol, particularly during the first weeks of treatment or after a dose increase.

Can I stop a GLP-1 medication if the side effects are too severe? Yes — but do not stop without consulting your provider first. If side effects are intolerable, your provider may recommend pausing dose escalation at your current level, reducing the dose temporarily, or adjusting the injection timing. Abrupt discontinuation is rarely necessary for side effect management alone, and many patients find that the adjustment period resolves on its own. If you and your provider decide discontinuation is the right choice, they can guide you through that process safely.

Do GLP-1 side effects get worse over time? For most patients, the opposite is true. GLP-1 side effects typically improve with time as the body adapts to the medication. Each dose increase may temporarily bring back mild symptoms, but these generally subside within one to two weeks. If side effects are worsening rather than improving over time at a stable dose, this is not normal and should be discussed with your provider.

Is hair loss from GLP-1 permanent? Based on available evidence, hair thinning associated with GLP-1 use — most commonly a pattern called telogen effluvium — is almost always temporary. Hair regrowth typically occurs within six to twelve months as the body stabilizes. Adequate protein and micronutrient intake during weight loss appears to reduce severity. If hair loss is severe or does not improve, evaluation by a dermatologist is appropriate.

Are GLP-1 medications safe if I have a history of thyroid disease? This depends on the specific thyroid condition. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take GLP-1 receptor agonists. These are absolute contraindications. Patients with other thyroid conditions — such as hypothyroidism or autoimmune thyroid disease — should discuss their individual history with their prescribing provider. Disclosing your full thyroid history before starting is essential.

Summary: What You Need to Know About GLP-1 Side Effects

GLP-1 receptor agonists are highly effective medications with a well-characterized side effect profile. The overwhelming majority of side effects are gastrointestinal, dose-dependent, and temporary. They reflect the mechanism the medication uses — slowing gastric emptying and activating brainstem satiety signals — and improve substantially as the body adjusts.

The most important things to remember:

• Eat smaller, lower-fat meals, eat slowly, and stay well hydrated
• Side effects are typically worst in the first two weeks at each new dose and improve from there
• Slow, flexible titration reduces side effect burden without compromising effectiveness
• Know the red flags — severe abdominal pain, inability to keep fluids down, neck swelling, jaundice, or signs of allergic reaction — and respond to them promptly
• Disclose your complete medical history to your provider before starting, particularly any history of thyroid cancer, pancreatitis, or gallbladder disease

If you have questions about whether GLP-1 therapy is appropriate for you, the providers at ZynoxRX are available to review your health history and help you make an informed decision.

References

Bhatt, D. L., et al. (2023). Gastrointestinal side effects of GLP-1 receptor agonists. Journal of Clinical Medicine, 12(4), 1452.

Eldor, R., et al. (2025). Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: A randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen. Diabetes Care, 48, 1607–1611.

Eli Lilly and Company. (2024). ZEPBOUND (tirzepatide) injection, for subcutaneous use [Prescribing Information]. Retrieved from the FDA website.

Feier, C. V. I., Vonica, R. C., Faur, A. M., Streinu, D. R., & Muntean, C. (2024). Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: A systematic literature review. International Journal of Molecular Sciences, 25(8), 4346. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050669/

Frontiers in Endocrinology. (2026). Do no harm: Managing nausea and vomiting in GLP-1 based obesity therapies. Frontiers in Endocrinology. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1788698/full

National Institutes of Health, PubMed Central. (2025). Alopecia as an emerging adverse effect associated with glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss: A scoping review. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12431796/

Novo Nordisk. (2024). WEGOVY (semaglutide) injection, for subcutaneous use [Prescribing Information]. Retrieved from the FDA website.

Sodhi, M., et al. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA.

The RX Index. (2026). GLP-1 long-term side effects: 2026 evidence map. https://therxindex.com/guides/glp-1-long-term-side-effects/

U.S. Food and Drug Administration. (2024). Prescribing information for semaglutide and tirzepatide products. Retrieved from FDA.gov.